Last reviewed · How we verify

Universidade Estadual Paulista Júlio de Mesquita Filho — Portfolio Competitive Intelligence Brief

Universidade Estadual Paulista Júlio de Mesquita Filho pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
General anesthesia General anesthesia marketed General anesthetic Anesthesiology
Chlorhexidine rinse Chlorhexidine rinse marketed Antimicrobial oral rinse Bacterial cell membrane and proteins Oral health / Dentistry
Lactobacillus reuteri Oral Drops Lactobacillus reuteri Oral Drops phase 3 Probiotic Gastroenterology / Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Seoul National University Hospital · 2 shared drug classes
  2. BioBalance Corporation · 1 shared drug class
  3. Chung-Ang University Gwangmyeong Hospital · 1 shared drug class
  4. CD Pharma India Pvt. Ltd. · 1 shared drug class
  5. CHU de Quebec-Universite Laval · 1 shared drug class
  6. Chuncheon Sacred Heart Hospital · 1 shared drug class
  7. Biocodex · 1 shared drug class
  8. Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universidade Estadual Paulista Júlio de Mesquita Filho:

Cite this brief

Drug Landscape (2026). Universidade Estadual Paulista Júlio de Mesquita Filho — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidade-estadual-paulista-j-lio-de-mesquita-filho. Accessed 2026-05-17.

Related